Form D · Biotechnology

Cresilon, Inc.

Brooklyn, NY · CIK 0001728054

Offering snapshot reported Jun 26, 2026 · SEC filing

Reported sold
$29M
Offering amount: $29M
Investors reported
217
Form D · investor count
Minimum accepted
$10K
Reported outside-investor minimum
First sale
Apr 24, 2026
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$14.5M$29MApr 29, 2026: $4,997,000.00Apr 29, 2026Jun 26, 2026: $28,999,199.00Jun 26, 2026

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$4,997,000 → $28,999,199
  • Reported investors21 → 217
  • Minimum accepted$12,000 → $10,000

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jun 26, 2026Amendment$28,999,199$24,002,199vs Apr 29, 2026217SEC filing
Apr 29, 2026Initial$4,997,000No comparison21SEC filing
Dec 8, 2025Initial$6,683,401No comparison55SEC filing
Sep 5, 2025Initial$17,172,969No comparison95SEC filing
Jan 31, 2025Initial$24,999,967No comparison237SEC filing
Oct 8, 2024Initial$17,243,350No comparison309SEC filing
Oct 18, 2022Initial$24,999,999No comparison308SEC filing
Feb 16, 2021Initial$24,464,276No comparison170SEC filing
Jan 12, 2018Initial$13,338,000No comparison55SEC filing

Offering details

Securities
Debt, Option to acquire
Exemptions
06c
Duration over one year
No
Business combination
No
Sales commissions
$3.43M
Finders' fees
$0
Form D file number
021-582305

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
Paulson Investment Company, LLC5670

Source: Form D, filed Jun 26, 2026. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Joseph Landolina Director, Executive
Scott Levine Executive
Isaac Miller Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
122 18 Th Street
Brooklyn, NY, 11215
Phone: (347) 435-2226